TNF Inhibitor denied as not FDA-approved for this use by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors as Not FDA-Approved

A "not FDA-approved" denial from Anthem Blue Cross indicates the plan's reviewer determined that the requested use — the specific TNF inhibitor, for the specific diagnosis, at the requested route or setting — does not correspond to an FDA-approved indication. This most commonly arises with off-label prescribing, where a TNF inhibitor approved for one condition is being used for a related but separately classified diagnosis.

This denial is worth scrutinizing carefully. First, verify whether the FDA actually has approved this agent for this indication — Anthem's review process can sometimes apply criteria to the wrong indication or outdated labeling. Second, even where use is genuinely off-label, many state laws and ERISA regulations require coverage of off-label use when supported by recognized compendia or standard-of-care guidelines. Your state's external review law may independently protect you.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File within the deadline on your denial letter. Request the exact version of the FDA-approval criteria Anthem applied, and the reviewer's qualifications. A full-and-fair review must consider all clinical evidence submitted.
• External independent review: Available after internal exhaustion on ACA-compliant plans. The window is generally up to approximately four months from final internal denial. An independent reviewer applies clinical — not only coverage-policy — standards.
• Expedited review: If delay would seriously jeopardize health.
• State law protections: Many states require insurer coverage of off-label use when supported by recognized compendia (e.g., NCCN Drugs & Biologics Compendium, Micromedex, or similar). Check your state's off-label coverage statute.

## Documentation to Gather

1. FDA prescribing label — print the current label from the FDA's DailyMed database for the exact TNF inhibitor prescribed and confirm the approved indications list. 2. Diagnosis precision — chart documentation, specialist notes, and ICD codes ensuring the diagnosis is coded with maximum specificity to align with the FDA-approved indication. 3. Compendia listing — if this is off-label use, your prescriber or pharmacist should identify whether the use is listed in a recognized compendium your state's insurance code references. 4. Prescriber medical-necessity letter — the clinician should cite the FDA-approved indication (if applicable), the applicable professional-society guideline organization, and why this patient's clinical presentation warrants this treatment. 5. Anthem's policy language — obtain the exact clinical policy used to issue the denial to understand precisely which FDA-approval criterion was not met.

## Criteria-Mapping Structure

| Anthem's FDA-Approval Criterion | Supporting Evidence | |---|---| | [Verbatim language from Anthem's policy] | [FDA label page/section, compendium citation, or guideline organization reference] |

Your appeal should distinguish between an indication that is genuinely unapproved versus one that Anthem's system has miscategorized. In either case, the FDA prescribing label is the authoritative source — never rely on remembered indications or dosing details. Verify all clinical facts against the current FDA label and Anthem's current published policy before submitting.